Business, energy, technology, markets and global industry news from Business News Today

HARMONi-GI3

PharmaDeviceNews HARMONi-GI3
Summit Therapeutics enters a pivotal phase for ivonescimab as the oncology developer deploys its $690.7 million cash position toward an upcoming FDA decision, HARMONi-3 data and an expanding late-stage lung cancer programme. Representative image.
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More